Cabot Brown - GW Pharmaceuticals Non-Executive Independent Director

Director

Mr. Cabot Brown is NonExecutive Independent Director of GW Pharmaceuticals PLC. Mr. Brown has over 25 years of experience in the financial industry. Mr. Brown is the Founder and Chief Executive Officer of Carabiner LLC, an advisory and private equity firm based in San Francisco and London that specializes in health care and education. Previously, Mr. Brown served as a Managing Director at GCA Savvian Group Corporationration, an international financial advisory firm, from 2011 to 2012 where he directed the firm efforts in the health care industry. Before joining GCA Savvian, Mr. Brown worked for ten years at Seven Hills Group, an investment banking group he cofounded where he also directed the firm health care activities. He also was Managing Director of Brown, McMillan Co., an investment firm he cofounded that sponsored buyouts and VC investments. From 1987 until 1995, Mr. Brown worked at Volpe, Welty Company, a boutique investment bank where he cofounded and ran the health care practice and served as a member of its Executive Committee. Mr. Brown started his finance career in New York, working in the investment banking departments of The First Boston Corporation and Lehman Brothers since 2013.
Age 52
Tenure 11 years
Professional MarksMBA
Phone(44) 1223 235667
Webwww.gwpharm.com
Brown holds an M.B.A. from Harvard Business School with high distinction as a George F. Baker Scholar and an A.B. cum laude in Government from Harvard College. Our board of directors believes Mr. Brown qualifications to serve as a member of our board include his financial expertise, his extensive experience in the health care industry and his years of experience in his leadership roles as a director and executive officer.

GW Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (3.55) % which means that it has lost $3.55 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.92) %, meaning that it created substantial loss on money invested by shareholders. GW Pharmaceuticals' management efficiency ratios could be used to measure how well GW Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 43.64 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. GW Pharmaceuticals Plc has a current ratio of 4.48, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist GW Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, GW Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like GW Pharmaceuticals Plc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for GWPH to invest in growth at high rates of return. When we think about GW Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Brian WestTradeweb Markets
44
Joseph ScaminaceParker Hannifin
67
Bradley CrewsTitan Machinery
N/A
Michael DominguezCDW Corp
45
Linda HartyParker Hannifin
60
Laura ThompsonParker Hannifin
56
Anton ChristiansonTitan Machinery
64
Robin SelatiCDW Corp
49
Kevin LoboParker Hannifin
55
John FinleyTradeweb Markets
61
Ake SvenssonParker Hannifin
68
Ryan MangoldTradeweb Markets
N/A
Debra WaltonTradeweb Markets
57
Donna ZarconeCDW Corp
60
Christopher ThompsonJacobs Solutions
72
Dame BarkerTradeweb Markets
58
Wolfgang SchmittParker Hannifin
72
John BodeTitan Machinery
67
Lynda ClarizioCDW Corp
57
Robert BohnParker Hannifin
66
Stan EricksonTitan Machinery
66
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom. Gw Pharma operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 1161 people. GW Pharmaceuticals Plc (GWPH) is traded on NASDAQ Exchange in USA and employs 1,161 people.

Management Performance

GW Pharmaceuticals Plc Leadership Team

Elected by the shareholders, the GW Pharmaceuticals' board of directors comprises two types of representatives: GW Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GWPH. The board's role is to monitor GW Pharmaceuticals' management team and ensure that shareholders' interests are well served. GW Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GW Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
William Waldegrave, Non-Executive Independent Director
Christopher Tovey, COO, Executive Director
Thomas Lynch, Non-Executive Independent Director
Catherine Mackey, Non-Executive Independent Director
Justin Gover, CEO, Director
Geoffrey Guy, Executive Chairman of the Board
James Noble, Non-Executive Deputy Chairman of the Board, Senior Independent Director
Julian Gangolli, Executive Director
Alicia Secor, Non-Executive Independent Director
Adam George, CFO, Company Secretary, Director
Cabot Brown, Non-Executive Independent Director
Stephen Wright, Research & Development Director, Executive Director
Darren Cline, Chief Commercial Officer, U.S.

GWPH Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GW Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards GW Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, GW Pharmaceuticals' short interest history, or implied volatility extrapolated from GW Pharmaceuticals options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Other Consideration for investing in GWPH Stock

If you are still planning to invest in GW Pharmaceuticals Plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the GW Pharmaceuticals' history and understand the potential risks before investing.
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
CEOs Directory
Screen CEOs from public companies around the world
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon